To access possible relationships between breast cancer subtypes (BCS) and patterns of distant metastasis in advanced breast cancer. Breast cancer patients with distant metastasis at two academic centers from 2000-2015 were retrospectively reviewed. The breast cancer was classified into four subtypes: hormone receptor (HR) +/ human epidermal growth factor receptor 2 (HER2) - (i.e., estrogen rece...

PURPOSE We report a retrospective exploratory analysis of the association of the research-based prediction analysis of microarray 50 (PAM50) subtype predictor with pathologic complete response (pCR) and event-free survival (EFS) in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial. EXPERIMENTAL DESIGN Gene expression profiling was performed using RNA from formalin-fixed paraffin-embedd...

PURPOSE The optimal method to assess human epidermal growth factor receptor 2 (HER2) status remains highly controversial. Before reporting patient HER2 results, American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines mandate that laboratories demonstrate ≥ 95% concordance to another approved laboratory or methodology. Here, we compare central laboratory HE...

BACKGROUND We sought to determine the predictive value of in situ mRNA measurement compared to traditional methods on a cohort of trastuzumab-treated metastatic breast cancer patients. METHODS A tissue microarray composed of 149, classified as HER2-positive, metastatic breast cancers treated with various trastuzumab-containing chemotherapy regimens was constructed. HER2 intracellular domain(I...

PURPOSE Glioblastoma multiforme (GBM) is the most aggressive human primary brain tumor and is currently incurable. Immunotherapies have the potential to target GBM stem cells, which are resistant to conventional therapies. Human epidermal growth factor receptor 2 (HER2) is a validated immunotherapy target, and we determined if HER2-specific T cells can be generated from GBM patients that will t...

The epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases activates signalling pathways regulating cellular proliferation and survival. HER2 is a non-ligand-binding member of this family and exerts its activity through heterodimerisation with other EGFR family members. HER2 functional activation promotes oncogenesis, leading to the investigation of HER2-direc...

Delta-human epidermal growth factor receptor 2 (HER2) is a splice variant of HER2, which lacks 16 amino acids in the extracellular domain. The aim of the present study was to elucidate the expression of delta‑HER2 and its clinicopathological correlation in Japanese patients with HER2‑overexpressing breast cancer. A total of 40 cases of HER2‑overexpressing breast cancer were investigated. The mR...

in this study, we synthesized herceptin conjugated magnetic nanoparticles (hmns) as an alternative probe to discover the levels of her2 (human epidermal growth factor receptor-2) in the surface of cells. these nanoparticles can be used by magnetic resonance imaging (mri) (non-invasive methods) for screening the patients with her2 positive or negative tumors. dextran coated iron oxide nanopartic...

Some recent evidence has suggested that HER2-low breast cancers (BC) are distinct entities. The prognostic impact of low expression HER-2 not yet well defined, and inconsistent results were reported. This study aims to evaluate the status on response neoadjuvant chemotherapy (NACT). We retrospectively analyzed HER2-negative BC patients treated with NACT from 2017 2022 in a single academic cente...